A 12-month randomised pilot trial of the Alzheimer's and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer's disease.
Alzheimer’s disease
Feasibility
Longitudinal
Music therapy
Non-pharmacological therapies
Physical activity
Randomised controlled trial
Randomised pilot trial
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
19 Apr 2023
19 Apr 2023
Historique:
received:
07
01
2022
accepted:
30
03
2023
medline:
20
4
2023
pubmed:
20
4
2023
entrez:
19
04
2023
Statut:
epublish
Résumé
The Alzheimer's and Music Therapy (ALMUTH) study is the first randomised controlled trial (RCT) design with 12 months of active non-pharmacological therapy (NPT) implementing music therapy (MT) and physical activity (PA) for participants with Alzheimer's disease (AD). The aim of the present article is to retrospectively examine the inclusion of mild-to-moderate Alzheimer's Disease patients into the main ALMUTH study protocol and to determine if continued inclusion of AD patients is warranted. The randomised pilot trial was conducted as a parallel three-arm RCT, reflecting the experimental design of the ALMUTH study. The trial was conducted in Bergen, Norway, and randomisation (1:1:1) was performed by an external researcher. The study was open label and the experimental design features two active NPTs: MT and PA, and a passive control (no intervention, CON) in Norwegian speaking patients with AD who still live at home and could provide informed consent. Sessions were offered once per week (up to 90 min) up to 40 sessions over 12 months. Baseline and follow-up tests included a full neuropsychological test battery and three magnetic resonance imaging (MRI) measurements (structural, functional, and diffusion weighted imaging). Feasibility outcomes were assessed and were determined as feasible if they met the target criteria. Eighteen participants with a diagnosis of mild-to-moderate AD were screened, randomised, and tested once at baseline and once after 12-months. Participants were divided into three groups: MT (n = 6), PA (n = 6), and CON (n = 6). Results of the study revealed that the ALMUTH protocol in patients with AD was not feasible. The adherence to the study protocol was poor (50% attended sessions), with attrition and retention rates at 50%. The recruitment was costly and there were difficulties acquiring participants who met the inclusion criteria. Issues with study fidelity and problems raised by staff were taken into consideration for the updated study protocol. No adverse events were reported by the patients or their caregivers. The pilot trial was not deemed feasible in patients with mild-to-moderate AD. To mitigate this, the ALMUTH study has expanded the recruitment criteria to include participants with milder forms of memory impairment (pre-AD) in addition to expanding the neuropsychological test battery. The ALMUTH study is currently ongoing through 2023. Norsk Forskningsråd (NFR) funded. Regional Committees for Medical and Health Research Ethics (REC-WEST: reference number 2018/206). gov: NCT03444181 (registered retrospectively 23 February 2018, https://clinicaltrials.gov/ct2/show/NCT03444181 ).
Sections du résumé
BACKGROUND
BACKGROUND
The Alzheimer's and Music Therapy (ALMUTH) study is the first randomised controlled trial (RCT) design with 12 months of active non-pharmacological therapy (NPT) implementing music therapy (MT) and physical activity (PA) for participants with Alzheimer's disease (AD). The aim of the present article is to retrospectively examine the inclusion of mild-to-moderate Alzheimer's Disease patients into the main ALMUTH study protocol and to determine if continued inclusion of AD patients is warranted.
METHODS
METHODS
The randomised pilot trial was conducted as a parallel three-arm RCT, reflecting the experimental design of the ALMUTH study. The trial was conducted in Bergen, Norway, and randomisation (1:1:1) was performed by an external researcher. The study was open label and the experimental design features two active NPTs: MT and PA, and a passive control (no intervention, CON) in Norwegian speaking patients with AD who still live at home and could provide informed consent. Sessions were offered once per week (up to 90 min) up to 40 sessions over 12 months. Baseline and follow-up tests included a full neuropsychological test battery and three magnetic resonance imaging (MRI) measurements (structural, functional, and diffusion weighted imaging). Feasibility outcomes were assessed and were determined as feasible if they met the target criteria.
RESULTS
RESULTS
Eighteen participants with a diagnosis of mild-to-moderate AD were screened, randomised, and tested once at baseline and once after 12-months. Participants were divided into three groups: MT (n = 6), PA (n = 6), and CON (n = 6). Results of the study revealed that the ALMUTH protocol in patients with AD was not feasible. The adherence to the study protocol was poor (50% attended sessions), with attrition and retention rates at 50%. The recruitment was costly and there were difficulties acquiring participants who met the inclusion criteria. Issues with study fidelity and problems raised by staff were taken into consideration for the updated study protocol. No adverse events were reported by the patients or their caregivers.
CONCLUSIONS
CONCLUSIONS
The pilot trial was not deemed feasible in patients with mild-to-moderate AD. To mitigate this, the ALMUTH study has expanded the recruitment criteria to include participants with milder forms of memory impairment (pre-AD) in addition to expanding the neuropsychological test battery. The ALMUTH study is currently ongoing through 2023.
TRIAL REGISTRATION
BACKGROUND
Norsk Forskningsråd (NFR) funded. Regional Committees for Medical and Health Research Ethics (REC-WEST: reference number 2018/206).
CLINICALTRIALS
RESULTS
gov: NCT03444181 (registered retrospectively 23 February 2018, https://clinicaltrials.gov/ct2/show/NCT03444181 ).
Identifiants
pubmed: 37076884
doi: 10.1186/s40814-023-01287-1
pii: 10.1186/s40814-023-01287-1
pmc: PMC10114372
doi:
Banques de données
ClinicalTrials.gov
['NCT03444181']
Types de publication
Journal Article
Langues
eng
Pagination
61Subventions
Organisme : Norges Forskningsråd
ID : 260576/ZB
Informations de copyright
© 2023. The Author(s).
Références
Scand J Psychol. 2010 Jun 1;51(3):237-45
pubmed: 20028488
Neuropsychol Rev. 2009 Mar;19(1):85-101
pubmed: 19214750
J Altern Complement Med. 2018 Jan;24(1):33-36
pubmed: 28714736
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
J Alzheimers Dis. 2015;50(1):19-25
pubmed: 26639954
Neuropsychiatr Dis Treat. 2015 Feb 04;11:291-6
pubmed: 25678794
Ann N Y Acad Sci. 2017 Jul;1400(1):33-45
pubmed: 28704888
Nat Rev Neurosci. 2014 Mar;15(3):170-80
pubmed: 24552785
Arch Clin Neuropsychol. 2010 Mar;25(2):146-52
pubmed: 20139109
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Neuropsychologia. 2010 Aug;48(10):3164-7
pubmed: 20452365
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Arch Intern Med. 2001 Jul 23;161(14):1703-8
pubmed: 11485502
Dementia (London). 2016 Nov;15(6):1326-1339
pubmed: 25425445
Front Psychol. 2013 Jul 09;4:334
pubmed: 23847555
PLoS One. 2014 Feb 26;9(2):e89642
pubmed: 24586929
Curr Sports Med Rep. 2017 Jan/Feb;16(1):19-22
pubmed: 28067736
Cochrane Database Syst Rev. 2018 Jul 23;7:CD003477
pubmed: 30033623
Am J Occup Ther. 2014 Jan-Feb;68(1):50-6
pubmed: 24367955
Epidemiology. 2007 Nov;18(6):805-35
pubmed: 18049195
Annu Rev Med. 2017 Jan 14;68:413-430
pubmed: 28099083
Yale J Biol Med. 2011 Jun;84(2):161-7
pubmed: 21698051
Neurology. 2015 Sep 8;85(10):898-904
pubmed: 26109713
BJOG. 2018 Dec;125(13):1716
pubmed: 29916205
Front Psychol. 2014 Sep 30;5:1096
pubmed: 25324805
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Clin Neuropsychol. 1984 Nov;6(4):433-40
pubmed: 6501581
Front Aging Neurosci. 2013 Nov 12;5:75
pubmed: 24282403
BMC Med Res Methodol. 2010 Jan 06;10:1
pubmed: 20053272
Dement Geriatr Cogn Dis Extra. 2015 Sep 04;5(3):296-308
pubmed: 26483829
Psychopharmacol Bull. 1988;24(4):641-52
pubmed: 3249766
J Geriatr Psychiatry Neurol. 2020 Jan;33(1):28-41
pubmed: 31203712
J Alzheimers Dis. 2015;50(2):443-53
pubmed: 26682695
Biomed Res Int. 2016;2016:2589276
pubmed: 27547756
BMC Med Res Methodol. 2010 Jul 16;10:67
pubmed: 20637084
J Alzheimers Dis. 2014;41(2):453-66
pubmed: 24625794
Alzheimers Dement (N Y). 2021 May 25;7(1):e12179
pubmed: 34095440
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
J Alzheimers Dis. 2018;64(4):1347-1358
pubmed: 29991131
Cortex. 2017 Mar;88:165-172
pubmed: 28142025
Lancet Neurol. 2011 Sep;10(9):819-28
pubmed: 21775213
Neurology. 2012 Apr 24;78(17):1323-9
pubmed: 22517108
BMC Med. 2016 Dec 22;14(1):215
pubmed: 28003033
Hippocampus. 2009 Oct;19(10):1030-9
pubmed: 19123237
P T. 2010 Apr;35(4):208-11
pubmed: 20498822
Front Psychol. 2011 Jun 09;2:110
pubmed: 21713060
West J Emerg Med. 2017 Oct;18(6):1075-1078
pubmed: 29085540
JAMA Neurol. 2019 Jul 15;:
pubmed: 31305929
Cochrane Database Syst Rev. 2004;(3):CD003477
pubmed: 15266489
Exp Aging Res. 2001 Jul-Sep;27(3):215-28
pubmed: 11441644
Alzheimers Dement (N Y). 2019 Jul 09;5:272-293
pubmed: 31334330
Alzheimers Dement. 2021 Mar;17(3):327-406
pubmed: 33756057
Front Med (Lausanne). 2018 Aug 31;5:245
pubmed: 30234118
Clin Interv Aging. 2018 Sep 04;13:1593-1603
pubmed: 30233156
Brain. 2016 Mar;139(Pt 3):662-73
pubmed: 26912638
J Alzheimers Dis. 2011;26(4):709-18
pubmed: 21694450
Ann N Y Acad Sci. 2022 Oct;1516(1):11-17
pubmed: 35851957
Lancet Neurol. 2014 Aug;13(8):788-94
pubmed: 25030513
PLoS One. 2012;7(12):e52508
pubmed: 23285071
Int J Geriatr Psychiatry. 2013 Aug;28(8):781-94
pubmed: 23080214
Dement Geriatr Cogn Disord. 2009;28(1):36-46
pubmed: 19628939
Neuropsychologia. 2012 Dec;50(14):3295-303
pubmed: 23000133
Front Aging Neurosci. 2020 Nov 25;12:594432
pubmed: 33324194
Transl Neurodegener. 2017 Jan 25;6:2
pubmed: 28149509
Malays Fam Physician. 2006 Aug 31;1(2-3):70-3
pubmed: 27570591
Ann N Y Acad Sci. 2015 Mar;1337:223-31
pubmed: 25773638
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2010 Jan;17(1):108-28
pubmed: 19657762
Brain. 2015 Aug;138(Pt 8):2438-50
pubmed: 26041611
Aging Ment Health. 2018 Sep;22(9):1097-1106
pubmed: 28691506
J Am Geriatr Soc. 2007 Feb;55(2):158-65
pubmed: 17302650
Clin Interv Aging. 2014 Oct 06;9:1669-76
pubmed: 25336931
Cochrane Database Syst Rev. 2015 Apr 15;(4):CD006489
pubmed: 25874613
Int Psychogeriatr. 2000 Mar;12(1):49-65
pubmed: 10798453
PLoS One. 2020 Nov 18;15(11):e0240862
pubmed: 33206656
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
Alzheimers Dement. 2019 Jul;15(7):888-898
pubmed: 31164314
Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):158-62
pubmed: 18525288
Int Psychogeriatr. 2014 Jan;26(1):9-18
pubmed: 23962667
PLoS One. 2022 Jun 30;17(6):e0270682
pubmed: 35771851
Memory. 2006 Feb;14(2):161-75
pubmed: 16484107